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Hepatitis C virus (HCV) infection leads to chronic liver disease,
but also to extra-hepatic manifestations.1 These include mixed
cryoglobulinemia, lymphoproliferative disorders, and renal
disease. HCV infection has been reported in association
with distinct histological patterns of glomerulonephritis in
native kidneys.2 Membranoproliferative glomerulonephritis
(MPGN) associated with type II cryoglobulinemia is the
predominant type of HCV-related glomerulonephritis.3 Less
common glomerulonephritis diseases have also been reported
in HCV-infected patients: these include MPGN without
88 L. Rostaing, N. Kamarcryoglobulinemia,4 membranous glomerulonephritis (MGN),4
focal segmental glomerular sclerosis,5–7 proliferative glomeru-
lonephritis,4,8,9 and ﬁbrillary10,11 and immunotactoid glomerul-
opathies.11 Other anecdotal case reports have been also
published: HCV-related IgA nephropathy,12 rapidly progres-
sive glomerulonephritis,13 and thrombotic microangiopathy
associated with cryoglobulinemic MPGN.14 However, whether
a causative effect between these glomerular diseases and HCV
infection exists is still unknown.
Kidney biopsies were performed in HCV-positive patients
before liver transplantation and in autopsy cases of patients
infected by HCV. Different patterns of HCV-related glomeru-
lonephritis were found in the majority of patients.15,16
Following renal transplantation, some glomerulonephritis
can recur on the graft17 and several occurrences of de novo
glomerulonephritis associated with HCV infection have been
reported. In addition to the HCV-related glomerulopathy
described above in native kidneys, acute transplant glomerulop-
athy,5 chronic transplant glomerulopathy,5,18 and renal throm-
botic micro-angiopathy associated with anticardiolipin
antibodies19 have been also previously described. In order to
avoid HCV infection recurrence on the kidney allograft, it is
advisable to treat with antiviral therapy, i.e. alpha-interferon
(aIFN) with or without ribavirin (RBV), those HCV (+)/
RNA (+) dialysis patients who are candidates for kidney
transplantation.
Herein, we provide an overview of renal diseases related to
HCV and their therapies, as well as the treatment options
available for HCV (+)/RNA (+) dialysis patients. We will
not mention, however, HCV infection-related complications
in the post-kidney transplantation setting.2. Membranoproliferative glomerulonephritis
More than 80%of patients with mixed cryoglobulinemia are in-
fected by HCV, and cryoglobulinemia is found in all patients
with HCV-related MPGN.3 Cryoglobulins of types I, II, and
III are immunoglobulins that precipitate at cold temperature.
HCV-associated cryoglobulinemic glomerulonephritis, often
with type II cryoglobulinemia, is related to the deposition in
the glomerulus of immune complexesmade by theHCVantigen,
anti-HCV immunoglobulin (Ig)G antibodies, and a rheumatoid
factor, which in most cases is an IgM kappa. Clinically, patients
present with proteinuria and microscopic hematuria. Nephrotic
syndrome and acute nephritic syndrome, with rapid deteriora-
tion of renal function, are observed in, respectively, 20% and
25% of patients.3,20 Fifty percent of patients have moderate re-
nal insufﬁciency,3 and hypertension is present in 80% of pa-
tients.20 HCV-related cryoglobulinemic renal disease is often
associated with extra-renal manifestations. The most frequently
observed are purpura, arthralgia, and peripheral neuropathy.21
Laboratory parameters reveal the presence of circulating
cryoglobulins, which are most commonly type II cryoglobulins
in which the rheumatoid factor is an IgM kappa. The comple-
ment components, C4 and C1q, are usually low. Serum C3 level
is also moderately decreased. Serum anti-HCV antibodies and
HCV RNA are detected in both the serum and the cryoprecip-
itate. HCV RNA concentrates in cryoprecipitate are 1000
fold higher than in the serum. Histological examination of kid-
ney biopsies usually reveals the presence of glomerular inﬁltra-
tion by activated macrophages. The glomerular basementmembrane shows double contours, which are caused by the
interposition of monocytes between the basement membrane
and the endothelium. Immunoﬂuorescence exhibits subendo-
thelial deposits of IgM, IgG, and the complement components.
On electron microscopy, large subendothelial deposits are pres-
ent. Vasculitis of small renal arteries is present in 30% of cases.
A Japanese group demonstrated the glomerular deposition of
HCV core antigen in patients with MPGN.22 In general, the re-
nal prognosis is good20; however, renal disease is the ﬁrst cause
of morbid-mortality in patients with mixed cryoglobulinemia.20
Some authors have reported many cases of MPGN without
cryoglobulinemia.23,24 However, the majority of patients who
presented with this renal disease had rheumatoid factor in the
sera, and some of them developed cryoglobulinemia on follow-
up. This suggests that cryoglobulins were already present in
the sera, possibly at very low levels, and so were not detected ini-
tially. Several later studies failed to ﬁnd any association between
MPGN and HCV in the absence of cryoglobulinemia.3,5,25
HCV-related MPGN associated with type III mixed cryo-
globulinemia has also been reported.263. Membranous glomerulonephritis
Several cases of MGN have been described in HCV-infected
patients.6,27,28 The clinical presentation and the histological
ﬁndings are similar to idiopathic MGN. Biologically, they
are characterized by normal complement levels, and the
absence of cryoglobulins and rheumatoid factors in the serum.
A Japanese group detected HCV core protein in the glomeruli
of two patients with MGN, suggesting that immune complexes
containing HCV proteins might be deposited in the glomerul-
i.29 In one study from Japan, 8.3% of patients with MGN were
anti-HCV (+)/HCV RNA positive compared with fewer than
1% in patients with other glomerulonephritis patterns (exclud-
ing MPGN). Finally, the prevalence of MGN was found to be
signiﬁcantly higher in HCV-positive compared to HCV-
negative renal-transplant patients.30 These ﬁndings support a
possible pathogenic role of HCV in the development of MGN.
4. HCV-related renal disease in cases of comorbid conditions
4.1. Human immunodeﬁciency virus (HIV) infection
Few data regarding glomerular lesions in patients with coexis-
ting HIV and HCV infections have been published. Renal
biopsies performed in HIV–HCV co-infected patients present-
ing with hematuria, nephrotic range proteinuria, renal insufﬁ-
ciency, and hypertension have revealed the presence of type I
or type III MPGN, MGN, or mesangial proliferative glomer-
ulonephritis.31,32,12,33 Cryoglobulinemia was detected in some
of patients with MPGN, and hypocomplementemia was found
in the majority of them. The clinical course of HCV-related re-
nal disease in patients co-infected by HIV is characterized by a
rapid progression to renal failure.32 The optimal treatment of
these patients is unknown. Anti-HCV therapy might be the
treatment of choice.
4.2. Diabetic nephropathy
A high prevalence of HCV infection was found in patients with
type II diabetic-related nephropathy.34 The slope of reciprocal
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than in HCV-negative patients with type II diabetic-related
glomerulosclerosis. HCV infection was an independent factor
associated with the slope of reciprocal serum creatinine.34
The authors concluded that HCV infection might alter the
progression of diabetic-related nephropathy.34 HCV was also
found to be a predictor factor of poorer renal survival in
diabetic patients.35 The mechanism of this observation is
unknown.5. Diagnosis
Patients infected by HCV should be routinely screened for
microalbuminuria, microscopic hematuria, hypertension, and
renal function, as well as for cryoglobulinemia, complement
factors, and rheumatoid factor. A kidney biopsy should be per-
formed in cases of proteinuria, impairment of renal function, or
cryoglobulinemia. This strategy will allow us to detect silent
glomerular disease that is related to HCV at an early stage.
Similarly, patients with MPGN or MGN should be
screened for HCV infection. This includes: liver-enzyme levels,
HCV serology with a 3D-generation enzyme-linked immuno-
sorbent assay, HCV RNA in the serum and in the cryoprecip-
itate, if available. A normal liver-enzyme level does not exclude
the diagnosis of HCV infection.6. Treatment
Cryoglobulinemic membranoproliferative glomeronephritis is
the most frequent HCV-related renal injury. Renal disease is
the ﬁrst cause of morbid-mortality in mixed cryoglobulinemia
patients.20 Hence, even if the HCV-related liver injury is not an
indication for anti-viral therapy, HCV-related renal disease re-
quires a speciﬁc treatment. This treatment relies on either anti-
HCV therapy alone in cases of moderate renal disease, or on
combined anti-viral and immunosuppressive therapies in cases
of severe renal disease, i.e., nephrotic syndrome and/or pro-
gressive renal failure, or diseases that are refractory to anti-
HCV therapy alone.
6.1. Symptomatic therapy
Blood-pressure control, diuretics, the blockade of the rennin–
angiotensin system using either angiotensin-converting enzyme
inhibitors (ACEIs) alone or combined with an angiotensin
receptor blockers (ARBs), as well as the treatment of hyperlip-
idemia, are of proven beneﬁt.36
6.2. Anti-HCV therapy
Because a link has been established between HCV infection
and the occurrence of cryoglobulinemic MPGN, anti-viral
therapies have been used in HCV-positive patients presenting
with glomerulonephritis in order to achieve clearance of
HCV from the serum and, consequently, to have a beneﬁcial
effect on renal injury.
6.2.1. Interferon-alpha
In the early 1990s, standard alpha-interferon (a-IFN) was used
alone at different doses, i.e. 3–10 MU three times a week:
unfortunately, the results were disappointing. In 15 patientswho had a complete clearance of HCV RNA after a-IFN ther-
apy, an improvement in renal function was observed.37 How-
ever, there was no effect on proteinuria and all patients
relapsed after a-IFN therapy was stopped. Later, in a prospec-
tive uncontrolled study, 14 patients experiencing an HCV-re-
lated glomerulonephritis were treated with a-IFN for 6 to
12 months.9 Overall, proteinuria signiﬁcantly decreased, while
renal function remained stable. In 11 patients, sera were tested
for HCV RNA while on this therapy. Patients who became
cleared of HCV RNA (n= 6) had a better outcome compared
to those who remained HCV RNA positive (n= 5). However,
virological and renal relapses were observed after completing
the therapy. In this study, in ﬁve patients, the use of oral pred-
nisone, in addition to a-IFN, had no effect on renal function.
In contrast, steroid pulses had a beneﬁcial effect in two pa-
tients. Finally, the use of cytotoxic agents, with or without
plasma exchange, was associated with a high rate of death
and a ﬂare-up in HCV viremia.9
6.2.2. Interferon alpha and ribavirin
During the last few years, a combined therapy of a-IFN, espe-
cially pegylated IFN, with ribavirin, has become the gold stan-
dard of HCV treatment because it has been found to be more
effective than a-IFN alone (See ‘‘Treatment of chronic hepati-
tis C virus infection: Recommendations for adults-I’’). This
has prompted physicians to treat HCV-related glomerulone-
phritis with this combination. However, published case reports
and uncontrolled studies have only included small numbers of
patients so far.
In a prospective uncontrolled study, 20 patients presenting
with MPGN (n= 17), membranous glomerulonephritis
(n= 2), and mesangioproliferative glomerulonephritis
(n= 1) were treated with a-IFN and either with or without
ribavirin.38 All patients were given a-IFN 3 MU three times
weekly. In cases of persistent HCV RNA at three months,
ribavirin was added at the daily dose of 15 mg/kg: treatment
was continued for 12 months. Four out of the 20 patients be-
came HCV RNA negative within the ﬁrst three months and,
consequently, did not receive ribavirin therapy. Only one out
of the 16 remaining patients who additionally received ribavi-
rin became cleared of HCV RNA within the serum. Seven pa-
tients underwent a ribavirin dose reduction due to adverse
events, mainly hemolytic anemia. Overall, both HCV RNA
concentration and proteinuria decreased signiﬁcantly. Serum-
albumin level, as well as both C3 and C4 complement-compo-
nent levels, increased signiﬁcantly. Renal function remained
stable. In this study, no data are provided regarding the out-
come of renal disease after cessation of anti-HCV therapy.
In order to reduce ribavirin-induced hemolytic anemia,
some authors have developed a high-performance liquid chro-
matography method to monitor the plasma ribavirin level, and
have reported on their ﬁrst treatment with concentration-con-
trolled ribavirin plus a-IFN therapy in HCV-related glomeru-
lar disease.39 The intended trough ribavirin plasma
concentration was 10–15 mmol/L. Four patients received stan-
dard a-IFN, two received pegylated a-IFN and ribavirin, and
one patient received ribavirin monotherapy because of poor
tolerance to a-IFN. Five of the patients had a sustained viro-
logical response 6–32 months after antiviral therapy was
stopped. One patient relapsed three months after completing
therapy, whereas one patient who was receiving ribavirin
monotherapy did not have a virological response. Serum-albu-
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in all patients. Glomerular ﬁltration rate improved in three pa-
tients and remained stable in four other patients. Despite mon-
itoring ribavirin plasma concentration, the main side-effect
observed was ribavirin-induced hemolytic anemia, which re-
quired a ribavirin-dose reduction, low-dose iron, and system-
atic erythropoietin support. An improvement in renal
histology has been also reported in a small number of
patients.40
More recently, 18 patients who had HCV-related cryoglob-
ulinemic MPGN were treated with a combined therapy of
standard or pegylated interferon and ribavirin.41 After a symp-
tomatic treatment of nephrotic-range proteinuria by furose-
mide, with or without ACEIs, and with or without plasma
exchange that was or was not associated with steroids, 18 pa-
tients received anti-HCV therapy, while seven other patients
did not receive any anti-viral therapy. Fourteen out of the 18
were treated with standard a-IFN at 3 MU, three times
weekly, plus ribavirin at 600–1000 mg/d, and the four other
patients received pegylated IFN at 1.5 lg/kg weekly with the
same dose of ribavirin. The mean duration of anti-HCV ther-
apy was 18 ± 10 months (range 6–24 months). The mean
duration of follow-up after completing anti-HCV treatment
was 16.7 ± 17.7 months (range 6–30 months). A sustained
virological response was observed in 67% of patients. Pegylat-
ed IFN was given in three virological responders and one non-
responder. After anti-HCV treatment, proteinuria and cryo-
globulin levels decreased. In addition, serum-albumin level in-
creased signiﬁcantly in virological responders compared to
both the non-responders, who were receiving the combination
therapy, and to the control patients, who were receiving any
anti-viral treatment. In contrast, serum-creatinine level re-
mained stable in all three groups. These data suggest that
anti-viral therapy should be given for a long period.
The major side effects of a-IFN can be ﬂu-like symptoms,
malaise, myalgia, asthenia, loss of weight, cardiovascular dis-
orders, hematological abnormalities, neurological disorders...
The side effects of a-IFN are enhanced in patients with im-
paired renal function compared to those with normal renal
function. This might be related to differences in a-IFN phar-
macokinetics. To date, two molecularly different pegylated
interferons are available, i.e., pegylated interferon alfa-2a (Peg-
asys, Hoffmann-La Roche, Basel, Switzerland) and pegylated
interferon alpha-2b (Peg-Intron, Schering-Plough, Berlin Ger-
many). The pegylation of aIFN results in an increase of its
half life. For both pegylated interferon formulations, renal
clearance accounts for a relatively smaller proportion of its to-
tal clearance than for non-pegylated interferons, i.e., 30%.42,43
However, pegylated IFN should be used with caution.
6.2.3. Ribavirin monotherapy
Despite the absence of a complete and sustained virological re-
sponse, ribavirin monotherapy has been shown to have a ben-
eﬁcial effect on HCV-related glomerulopathy in
immunocompetent patients,44 as well as in renal-45 and liver-
transplant patients.46
Ribavirin, when given alone or in association with a-IFN,
is responsible for hemolytic anemia, especially in cases of re-
nal-function impairment. Thus, it is widely admitted that riba-
virin dosage should be adapted to creatinine clearance rather
than to body weight,47–49 as has been previously recom-
mended. Ribavirin plasma concentration predicts ribavirin-in-duced anemia.50 Hence, in patients with impaired renal
function, ribavirin should be given with caution. The accumu-
lation of ribavirin induces hemolytic anemia. Severe chronic
hemolysis is responsible for iron overload, liver iron deposi-
tion, and an acceleration in liver ﬁbrosis progression.51
6.3. Immunosuppressive therapy
In the past, patients with mixed cryoglobulinemia, with or
without renal involvement, were treated by plasma exchange
to remove circulating cryoglobulins from the plasma and, con-
sequently, to diminish the deposition of immune complexes in
the kidney.21 Cyclophosphamide was also used to improve re-
nal disease by suppressing B lymphocyte stimulation and cryo-
globulin production.21 Steroid pulses were administrated to
treat glomerular inﬁltration abnormalities.21 Low doses of oral
steroids were also given to some patients.21 Previous uncon-
trolled studies that included a small number of patients treated
with these therapies showed that this regime often controlled
the acute phase of the disease, but was often poorly tolerated.
The ﬂare-up of HCV RNA concentration observed during
immunosuppressive therapy may be harmful to HCV related-
liver disease.
6.3.1. Rituximab
Recently, rituximab, a human-mouse chimeric monoclonal
antibody that reacts with the CD20 antigen and, thus, directly
and selectively targets the B cells, has proved effective and very
well tolerated in patients with B-cell non-Hodgkin lymphomas.
Hence, it is used to treat mixed cryoglobulinemia and HCV-re-
lated cryoglobulinemic MPGN.
Two patients, with HCV-related cryoglobulinemic MPGN,
were treated with rituximab at four weekly doses of 375 mg/
m2.52 They were unresponsive to conventional treatments,
including a-IFN, plasmapheresis, steroids, and either cyclo-
phosphamide or 2-chlorodeoxyadenoyne. A rapid response,
and the disappearance of proteinuria and inactive urinary sed-
iment, was observed in one patient who had a recent onset of
nephritis. No improvement was noticed in the second patient
when rituximab was interrupted after two infusions due to a
thrombosis of the retinal artery. In the patient who completed
rituximab therapy, HCV RNA concentration showed minimal
ﬂuctuations.52
Later, six patients who had HCV-related cryoglobulinemic
glomerulonephritis were treated with rituximab.53 One patient
received the standard four weekly doses, and the ﬁve other pa-
tients were treated by the standard protocol, plus two addi-
tional infusions at one and two months later. Proteinuria
was decreased in all patients. Serum-creatinine level decreased
in two patients, increased in one patient, and remained stable
in the three other patients. Interestingly, HCV viral load de-
creased or remained stable in all patients. Rituximab has been
also found to be effective for the treatment of HCV-related
type II cryoglobulinemic MPGN when used as a ﬁrst-line
therapy.54
A renal-transplant patient who was experiencing a de novo
HCV-related type III cryoglobulinemic MPGN was treated
with rituximab therapy: he had a clearance of cryoglobuline-
mia, a decrease in proteinuria, and no change in serum creat-
inine or HCV RNA.55 Rituximab was efﬁcient in treating de
novo cryoglobulinemic MPGN in HCV-positive or -negative
renal-transplant patients, but is associated with a high rate
Hepatitis C virus infection in nephrology patients 91of infectious complications, which might be related to the
impairment of T- and B-cell functions that these patients expe-
rience.55 Further controlled randomized studies are required to
deﬁne the exact indications of rituximab, the dose of rituximab
required, as well as its long-term effect on HCV liver disease.
6.3.2. Immunosuppressive therapy in the case of acute and severe
disease
During the acute phase, plasmapheresis and steroid pulses
might be used to remove circulating cryoglobulins from the
plasma and to treat the glomerular inﬁltration abnormalities,
respectively. Even in the absence of controlled randomized
studies that compared the use of anti-CD20 monoclonal anti-
bodies, i.e. rituximab (RTX) to IV cyclosphosphamide, ritux-
imab therapy should be preferred to cyclophosphamide. This
is supported by two very recent publications. In the ﬁrst, Saa-
doun et al.56 examined whether treatment of HCV-mixed cryo-
globulinemia (MC) may target either the viral trigger (HCV)
or the downstream B-cell clonal expansion. In a prospective
cohort study they included 38 HCV-MC patients who received
(i) a combination of RTX (375 mg/m2) once a week for one
month followed by Peg-interferon-alpha (Peg-IFN-alpha; 2a,
180 microg or 2b, 1.5 microg/kg) weekly plus RBV (600–
1200 mg) daily for 48 weeks or (ii) Peg-IFN-alpha/ribavirin
with the same modalities (n= 55). In the whole population
of HCV-MC patients (n= 93), a complete clinical response
was achieved in 73.1% (68 of 93), cryoglobulin clearance in
52.7% (49 of 93), and a sustained virologic response in
59.1% (55 of 93). Compared with Peg-IFN-alpha/ribavirin,
rituximab plus Peg-IFN-alpha/ribavirin-treated patients had
a shorter time to clinical remission (5.4 ± 4 vs.
8.4 ± 4.7 months, P= .004), better renal response rates
(80.9% vs. 40% of complete response, P= .040), and higher
rates of cryoglobulin clearance (68.4% vs. 43.6%, P= .001)
and clonal VH1-69(+) B-cell suppression (P< .01). Treat-
ment was well tolerated with 11% of discontinuation resulting
from antiviral therapy and no worsening of HCV RNA under
rituximab. The second study included fewer patients, i.e. 37
which presented with HCV-related MC.57 The patients were
given a combination of Peg-IFN-alpha (2a: 180 mug or 2b:
1.5 mug/kg) weekly plus RBV (1000 or 1200 mg) daily for
48 weeks, with (n= 22) or without (n= 15) RTX (375 mg/
m2) once a week for one month followed by two 5-monthly
infusions (PIRR). Complete response was achieved in 54.5%
(12/22) and in 33.3% (5/15) of patients who received PIRRTable 1 Treatment of HCV-related glomerulonephritis.
Patients with moderate proteinuria and non-rapid but progressive renal f
Symptomatic treatment: Anti-HCV therapy for at least 12 months
Standard a-interferon 3 MU three times/week or pegylated a -IFN 1.5 lg
Ribavirin: dose adapted to the creatinine clearance or to a trough plasma
support
Patients with nephrotic-range proteinuria and/or progressive renal failure
Symptomatic therapy: Furosemide, angiotensin-converting enzyme inhibi
antagonist (ARBs)
Plasma exchange: 3 L of plasma three times/week for 2 or 3 weeks
Rituximab: 375 mg/m2 week for 4 weeks* or cyclophosphamide: 2 mg/kg
Methylprednisolone pulses: 0.5–1 g/d for three consecutive days
Anti-HCV therapy (see above).
* Additional infusions of rituximab might be given in cases of early relapand Peg-IFN-alpha/RBV, respectively (P< .05). Clearance
of HCV RNA and conversion of B-cell populations from oli-
goclonal to polyclonal in liver, bone marrow, and peripheral
blood was maintained for up to three years in 10 of 12
(83.3%) and in 2 of 5 (40%) patients receiving PIRR and
Peg-IFN-alpha/RBV, respectively (P< .01). Cryoproteins in
22.7% (5/22) of patients with PIRR and in 33.3% (5/15) with
Peg-IFN-alpha/RBV persisted despite sustained HCV RNA
clearance. No response occurred in remaining ﬁve patients of
both groups. PIRR therapy is well tolerated and more effective
than Peg-IFN-alpha/RBV combination in HCV-related MC.
Its effect may last for more than three years. The ﬁndings of
these two studies indicate that rituximab combined with Peg-
IFN-alpha/ribavirin is well tolerated, is more effective than
Peg-IFN-alpha/ribavirin, and has long-lasting effects on
HCV-MC.
6.4. Recommendations (Table 1)
All patients should be treated with ACEIs in association or not
with ARBs, as well as with anti-HCV therapy. The latter relies
on a combined anti-viral therapy of standard or pegylated IFN
and ribavirin. We recommend the treatment of patients for at
least 48 weeks, and the continuation of anti-viral therapy, even
in the absence of a decrease in HCV RNA concentration of 2-
log at week 12. Clinicians should be aware that after HCV
RNA clearance, cryoglobulinemia persists for a long period.
Ribavirin doses should be adapted according to creatinine
clearance in order to avoid its main side effect, i.e., hemolytic
anemia. Combined anti-viral and immunosuppressive thera-
pies may be the treatment of choice for patients with severe re-
nal disease, i.e., nephrotic syndrome and/or progressive renal
failure, or diseases that are refractory to anti-HCV therapy
alone.
HCV treatment in the chronic kidney disease (CKD) CKD
population: The AASLD (American Association for the Study
of Liver Diseases) has published guidelines for the CKD pop-
ulation stating that ‘‘when HCV infection is identiﬁed in per-
sons with CKD, interferon-based antiviral treatment must be
considered, but the regimen will vary depending on the kidney
disease. . .The decision to treat must take into account the com-
peting severities of the CKD and the chronic liver disease, the
risks of the treatment itself, and whether there are comorbid
conditions that may affect morbidity and mortality, such as
cardiovascular disease’’.58ailure:
/kg/week
concentration of 10–15 mmol/L with or without erythropoietin
:
tor (ACEIs) alone or combined with an angiotensin receptor
/d for 2–4 months
se after conventional therapy.
92 L. Rostaing, N. KamarThe kidneys play a major role in the catabolism and ﬁltra-
tion of both interferon and ribavirin; thus, their clearances
may be affected in subjects with CKD.59,60 The clearance of
pegylated interferon is affected in those with CKD, although
hemodialysis does not affect its clearance.61 Hence, the
AASLD guidelines recommend subcutaneous weekly doses
of 1 lg/kg of peginterferon alpha-2b and of 135 lg of peginter-
feron alpha-2a58 to patients with stage 3–5 CKD. Because
ribavirin is eliminated by the kidney, and if overdosed might
result in dramatic anemia,62 ribavirin therapy is contraindi-
cated when creatinine clearance is <50 mL/min. Hence, most
data regarding HCV treatment in the CKD population deal
with the use of either standard a-interferon or a-pegylated
interferon.
With regards to end-stage kidney-disease (ESKD) patients
who are chronically treated by dialysis, Casanovas-Taltavull
et al. reviewed two meta-analyses (Meta-1 and Meta-2) pub-
lished in 2008. From these they analyzed the SVRs, any ad-
verse effects, and the reasons for discontinuing aIFN
treatment in dialysis patients.63 The Meta-1 study analyzed re-
sults obtained from 645 patients; the Meta-2 study used data
from 459 patients (19 studies were duplicated). Overall, the
SVR was 40%; SVR in genotype 1 was 33%, with pegylated
interferon providing few additional beneﬁts over conventional
alpha-interferon. Adverse events, such as typical ﬂu-like syn-
drome occurred in 41% of patients, requiring withdrawal of
antiviral treatment in 11% of them. A high rate of anemia
was also documented, although the use of recombinant eryth-
ropoietin, intravenous iron administration, or transfusions was
not generally reported. A typical ﬂu-like syndrome occurred in
41% of patients, which required withdrawal of antiviral treat-
ment in 11%. Severe adverse events were divided into the fol-
lowing groups: hormonal (thyroid), bone pain, cytopenia,
gastrointestinal, immunological (prior graft rejection), central
nervous system, cardiovascular, and infectious problems. The
reviewers of these meta-analyses pointed out any bias in the
selection criteria of candidates for treatment, limitations re-
lated to the number and type of adverse effects (as well as their
clinical evaluation), and discrepancies in cases of discontinua-
tion of treatment or loss to follow-up.
With regards toMeta-1, the primary outcome was a SVR (as
a measure of efﬁcacy); the secondary outcome was the drop-out
rate (as a measure of tolerability).64 They identiﬁed 13 prospec-
tive studies, which were controlled clinical trials that included
539 unique patients, of whom10 (76.9%) patients were receiving
maintenance dialysis. Pooling of these studies’ results showed a
signiﬁcant increase in viral response of patients treated with
antiviral therapy compared to patients who did not receive
any therapy (controls). The pooled odds ratio (OR) of failure
to obtain a SVR was 0.081 [95% conﬁdence intervals (CI),
0.029–0.230], p= 0.0001. The pooled OR of drop-out rate
was signiﬁcantly increased in treated versus control patients,
OR= 0.389 (95%CI, 0.155–0.957), p= 0.04. The studies were
heterogeneous with regard to viral response and drop-out rate.
In the subset of clinical trials (n= 6) involving only dialysis pa-
tients receivinga-IFNmonotherapy for chronicHCV, therewas
a signiﬁcant difference in the risk of failure to obtain a SVR
(study vs. control patients), OR = 0.054 (95% CI, 0.019;
0.150), p= 0.0001. No difference in the drop-out rate between
study and control patients was shown [OR = 0.920 (95% CI,
0.367; 2.311), NS].Meta-1 showed that viral response was great-
er in patients with chronic kidney disease who received antiviraltherapy than in controls.No differences in the drop-out rates be-
tween study and control patients occurred in the subgroup of
dialysis patients on a-IFN monotherapy.64
With regards to Meta-2, the authors took into account
those chronic dialysis patients with chronic HCV infection
who were either treated with a IFN or pegaIFN, with or with-
out ribavirin.65 They searched on MEDLINE for indexed
studies since 1966, and only selected studies with a sample size
greater than 10. They looked for the following parameters:
SVR at six months after treatment, rate of treatment discontin-
uation caused by adverse events, and factors associated with
these outcomes. They analyzed 20 studies that contained 459
aIFN-treated patients, three studies that contained 38 pe-
gaIFN-treated patients, and two studies that contained 49 pe-
gaIFN and ribavirin-treated patients. The overall SVR rate
was 41% (95% conﬁdence interval [CI], 33–49) for aIFN
and 37% (95% CI, 9–77) for peg a IFN. Treatment-discontin-
uation rates were 26% (95% CI, 20–34) for aIFN and 28%
(95% CI, 12–53) for pegaIFN. SVR was higher, with three mil-
lion units (MU) or higher of aIFN at three times weekly, with
lower mean amounts of HCV RNA, lower rates of cirrhosis, a
HCV genotype 1, or elevated transaminase, though these ﬁnd-
ings were not statistically signiﬁcant.
Treatment-discontinuation rates were greater in studies
using larger doses. Hence, side-effects from alpha-interferon
were numerous, particularly in the ESKD population. The
main side effects were fatigue/weakness and loss of appetite,
which may lead to weight loss and, thus, ﬂuid overload if
dry weight is not adapted accordingly. Many patients also
developed anemia, which often requires commencement or in-
creased treatment with erythropoietin-stimulating agents; in
addition, seizures can occur if there is ﬂuid overload and
hypertension. The limitations of these meta-analyses were pub-
lication bias, there were few randomized controlled trials, and
there were limitations in generalizability of all hemodialysis
patients. In conclusion, alpha-IFN treatment of hemodialysis
patients resulted in an SVR rate of 41%. Thus, a higher weekly
dose of aIFN, a lower mean level of pre-treatment HCV RNA,
a lower rate of cirrhosis, an HCV genotype different from 1,
and/or decreased transaminase levels may all be associated
with greater SVR rates.65
A more recent meta-analysis has been published on a group
of 770 hemodialysis patients with chronic HCV infection, in
which the authors evaluated factors that were associated to
SVR after a-pegylated or standard a-IFN monotherapy.
Twenty-one studies on a-IFN-alfa2a or a-IFN-alfa2b (491 pa-
tients), and 12 on pegylated-IFN-alfa2a or PEG-IFN-alfa2b
(279 patients), were evaluated. The pooled SVRs for standard
and pegylated a-IFN monotherapy in random-effect models
were 39.1% (95% CI, 32.1–46.1) and 39.3% (95% CI, 26.5–
52.1), respectively. Pooled dropout rates were 22.6% (95%
CI, 10.4–34.8) and 29.7% (95% CI, 21.7–37.7), respectively.
Female gender, HCV-RNA copies per mL, HCV genotype,
alanine transaminase pattern, duration of infection, stage of li-
ver ﬁbrosis, and treatment duration were not associated with
SVR. Only an age less than 40 years was signiﬁcantly associ-
ated with SVR (odds ratio, 2.17; 95% CI, 1.03–4.50).66
There are only few limited reports that describe the com-
bined use of (peg) alpha-interferon and ribavirin in dialysis pa-
tients. With regard to this combined therapy, the AASLD
guidelines state that ‘‘Ribavirin can be used in combination
with interferon with a markedly reduced daily dose with care-
Hepatitis C virus infection in nephrology patients 93ful monitoring for anemia and other adverse effects’’.58 The
largest series published so far on the combined use of peginter-
feron alpha-2a plus ribavirin in hemodialysis patients obtained
a SVR rate of 97% (34/35) in the treated patients (peginterfer-
on alpha-2a plus ribavirin) vs. 0% (0/35) in untreated con-
trols.67 These ﬁndings have not been conﬁrmed in further
reports where the SVR rate ranges between 7% and 71%68.
Treatment of acute HCV infection in CKD patients: In the
general population, with regard to the treatment of acute HCV
infection, the AASLD guidelines state that ‘‘Treatment can be
delayed for 8–12 weeks after acute onset of hepatitis to allow
spontaneous resolution.
Although excellent results were achieved using standard
interferon monotherapy, it is appropriate to consider the use
of peginterferon  Until more information becomes available,
no deﬁnitive recommendation can be made about the optimal
duration needed for treatment of acute hepatitis C; however, it
is reasonable to treat for at least 12 weeks and 24 weeks may
be considered’’.58
In dialysis patients, Liu et al. have very recently published
their experience regarding the treatment of acute HCV infec-
tion. They included 35 dialysis patients that had no spontane-
ous clearance of HCV at 16 weeks after acute HCV infection.
They were thus then given a course of peginterferon alpha 2a
at 135 lg weekly for 24 weeks.69 They compared the results
with those from a historical series of 36 hemodialysis patients
who had acute hepatitis C, but had not received treatment. The
rate of SVR in their treatment group was signiﬁcantly higher
than the rate of spontaneous HCV clearance in the control his-
torical series group (88.6% vs. 16.7%). All but one patient had
a rapid virologic response (undetectable HCV RNA levels at
four weeks of therapy), and all patients who received more
than 12 weeks of therapy had early and end-of-treatment viro-
logic responses. All patients who had clearance of HCV by
16 weeks had undetectable HCV RNA levels during and at
the end of follow-up. Liu et al. conclude that ‘‘Pegylated
IFN alfa-2a monotherapy is safe and efﬁcacious for hemodial-
ysis patients with acute hepatitis C. It is suggested that patients
without spontaneous clearance of HCV by week 16 should re-
ceive this therapy’’.69
In addition, dialysis patients who were cleared of the
HCV virus after antiviral therapy, and received kidney
transplantation, did not present with HCV reactivation, de-
spite heavy immunosuppression.70 Hence, 16 HCV seroposi-
tive/HCV RNA-positive hemodialysis patients who were
treated with IFN-alpha (9 MU/wk during 6 or 12 months)
underwent kidney transplantation 38 months (range, 2–57)
after alpha-IFN therapy. At kidney transplantation, HCV
viremia was negative in all patients. Immunosuppression re-
lied on anticalcineurin agents with or without steroids and/
or antimetabolites; in addition, 12 of them received induc-
tion therapy with antithymocyte globulins; at the last fol-
low-up after kidney transplantation, i.e. 22.5 months
(range, 2–88), HCV viremia remained negative in all pa-
tients.70 Recently, we have assessed the persistence of HCV
infection in 26 HCV seropositive kidney-transplant patients
currently receiving immunosuppressants, and who were for-
merly infected with HCV, i.e., they had eliminated HCV
either spontaneously or after interferon-a therapy while on
hemodialysis.71 No biochemical or virological relapse was
seen during the median posttransplant follow-up of
10.5 years (range: 2–16) in those patients who receivedimmunosuppressive therapy that included calcineurin inhibi-
tors (100%), and/or steroids (62%), and/or antimetabolites
(94%). At the last follow-up, all had undetectable HCV
RNA according to the conventional tests that were repeated,
on average, ﬁve times (range, 1–15). We also looked for
residual HCV RNA in their plasma and peripheral blood-
mononuclear cells (PBMCs) (stimulated or not in culture)
with an ultrasensitive RT-PCR assay, followed by Southern
blotting for PBMCs: no HCV genomic RNA was detected in
the plasma samples or in the unstimulated and stimulated
PBMCs. Thus, an absence of a relapse of HCV in formerly
HCV-infected immunocompromised patients suggests com-
plete eradication of HCV after its elimination while on dial-
ysis.71 These ﬁndings highlight the fact that HCV-positive
dialysis patients who have a SVR after completion of al-
pha-(peg) interferon therapy are really cured of HCV.References
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